Details of the Drug
General Information of Drug (ID: DM1D90W)
Drug Name |
Tropicamide
|
|||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Bistropamide; Epitromina; Mydral; Mydriacyl; Mydriafair; Mydriaticum; Mydrum; OcuTropic; Opticyl; Paremyd; Tropicacyl; Tropicamida; Tropicamidum; Tropikamid; Tropimil; Visumidriatic; Akorn Brand of Tropicamide; Alcon Brand of Tropicamide; Bournonville Brand of Tropicamide; Cahill May Roberts Brand of Tropicamide; Chauvin Brand of Tropicamide; Colircusi Tropicamida; Medical Ophthalmics Brand of Tropicamide; Minims tropicamide; Novartis Brand of Tropicamide; Ocu Tropic; Ocumed Brand of Tropicamide; Ocusoft Brand of Tropicamide; Pharmafair Brand of Tropicamide; Rivex Brand of Tropicamide; Triaminic DM; Tropicamide Alcon Brand; Tropicamide Chauvin Brand; Tropicamide Faure; Tropicamide Minims; Tropicamide Monofree; Tropicamide Novartis Brand; Tropicamide Ocumed Brand; Tropicamide Pharmafair Brand; Tropicamide Rivex Brand; Stulln Brand 1 of Tropicamide; Stulln Brand 2 of Tropicamide; T 9778; I-Picamide; Mydriacyl (TN); Ocu-Tropic; Ro 1-7683; Spectro-Cyl; Tropicamida [INN-Spanish]; Tropicamidum [INN-Latin]; Tropicamide [USAN:INN:BANJAN]; Tropicamide (JP15/USP/INN); Tropicamide Monohydrochloride, (R)-Isomer; Tropicamide Monohydrochloride, (S)-Isomer; Tropicamide, (R)-Isomer; Tropicamide, (S)-Isomer; N-Ethyl-N-(4-pyridylmethyl)tropamid; N-Ethyl-N-(4-pyridylmethyl)tropamide; N-ethyl-n-(g-picolyl)tropamide; Tropicamide, (+-)-Isomer; N-Ethyl-2-phenyl-N-(4-pyridylmethyl)hydracrylamide; N-Ethyl-2-phenyl-N-4-[-pyridyl-methyl]hydracrylamide; N-Ethyl-alpha-(hydroxymethyl)-N-(4-pyridinylmethyl)benzeneacetamide; N-ethyl-3-hydroxy-2-phenyl-N-(pyridin-4-ylmethyl)propanamide; (+-)-N-Ethyl-2-phenyl-N-(4-pyridylmethyl)hydracrylamide
|
|||||||||||||||||||
Indication |
|
|||||||||||||||||||
Therapeutic Class |
Diagnostic Agents
|
|||||||||||||||||||
Drug Type |
Small molecular drug
|
|||||||||||||||||||
Structure | ||||||||||||||||||||
3D MOL | 2D MOL | |||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 284.35 | ||||||||||||||||||
Topological Polar Surface Area (xlogp) | 1.5 | |||||||||||||||||||
Rotatable Bond Count (rotbonds) | 6 | |||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | |||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 3 | |||||||||||||||||||
ADMET Property | ||||||||||||||||||||
Chemical Identifiers |
|
|||||||||||||||||||
Cross-matching ID | ||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Mydriasis | |||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | LA11.62 | |||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||||||||
Drug-Drug Interaction (DDI) Information of This Drug
Coadministration of a Drug Treating the Disease Different from Tropicamide (Comorbidity)
|
Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug
References
1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7319). | ||||
---|---|---|---|---|---|
2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 040064. | ||||
3 | Vuori ML, Kaila T, Iisalo E, Saari KM: Systemic absorption and anticholinergic activity of topically applied tropicamide. J Ocul Pharmacol. 1994 Summer;10(2):431-7. doi: 10.1089/jop.1994.10.431. | ||||
4 | Tropicamide ophthalmic solution reduces clozapine-induced sialorrhea: a case report Psychiatry and Clinical Psychopharmacology. 2017 Jul 8;27(4):431-434. | ||||
5 | The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 rec... Psychopharmacology (Berl). 2007 Oct;194(3):347-59. | ||||
6 | Zebrafish M2 muscarinic acetylcholine receptor: cloning, pharmacological characterization, expression patterns and roles in embryonic bradycardia. Br J Pharmacol. 2002 Nov;137(6):782-92. | ||||
7 | Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7. | ||||
8 | 6beta-Acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors. J Med Chem. 1998 Jun 4;41(12):2047-55. | ||||
9 | Diphenidol-related diamines as novel muscarinic M4 receptor antagonists. Bioorg Med Chem Lett. 2008 May 1;18(9):2972-6. | ||||
10 | Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. | ||||
11 | cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8. | ||||
12 | Chloro-substituted, sterically hindered 5,11-dicarbo analogues of clozapine as potential chiral antipsychotic agents. J Med Chem. 1990 Feb;33(2):809-14. | ||||
13 | Synthesis and pharmacological evaluation of a series of 4-piperazinylpyrazolo[3,4-b]- and -[4,3-b][1,5]benzodiazepines as potential anxiolytics. J Med Chem. 1989 Dec;32(12):2573-82. | ||||
14 | Synthesis of clozapine analogues and their affinity for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1981 Sep;24(9):1021-6. | ||||
15 | Nocardimicins A, B, C, D, E, and F, siderophores with muscarinic M3 receptor inhibiting activity from Nocardia sp. TP-A0674. J Nat Prod. 2005 Jul;68(7):1061-5. | ||||
16 | Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979): 199-255. [PMID: 376469] | ||||
17 | Katz IR, Sands LP, Bilker W, DiFilippo S, Boyce A, D'Angelo K "Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride." J Am Geriatr Soc 46 (1998): 8-13. [PMID: 9434659] | ||||
18 | Multum Information Services, Inc. Expert Review Panel. | ||||